Precision BioSciences Inc (DTIL) - Total Assets
Based on the latest financial reports, Precision BioSciences Inc (DTIL) holds total assets worth $125.92 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Precision BioSciences Inc - Total Assets Trend (2016–2025)
This chart illustrates how Precision BioSciences Inc's total assets have evolved over time, based on quarterly financial data. Also see Precision BioSciences Inc market cap and net worth for the company's overall valuation and market capitalisation.
Precision BioSciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Precision BioSciences Inc's total assets of $125.92 Million consist of 76.9% current assets and 23.1% non-current assets. Review DTIL total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 71.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.17 Million | 0.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Precision BioSciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Precision BioSciences Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Precision BioSciences Inc's current assets represent 76.9% of total assets in 2025, a decrease from 95.9% in 2016.
- Cash Position: Cash and equivalents constituted 71.8% of total assets in 2025, down from 94.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 0.8% of total assets.
Precision BioSciences Inc Competitors by Total Assets
Key competitors of Precision BioSciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Precision BioSciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.82 | 5.18 | 5.02 |
| Quick Ratio | 12.82 | 5.18 | 4.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $84.41 Million | $56.69 Million | $146.57 Million |
Precision BioSciences Inc - Advanced Valuation Insights
This section examines the relationship between Precision BioSciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.51 |
| Latest Market Cap to Assets Ratio | 1.19 |
| Asset Growth Rate (YoY) | 13.2% |
| Total Assets | $154.42 Million |
| Market Capitalization | $184.10 Million USD |
Valuation Analysis
Above Book Valuation: The market values Precision BioSciences Inc's assets above their book value (1.19x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Precision BioSciences Inc's assets grew by 13.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Precision BioSciences Inc (2016–2025)
The table below shows the annual total assets of Precision BioSciences Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $154.42 Million | +13.22% |
| 2024-12-31 | $136.39 Million | -14.64% |
| 2023-12-31 | $159.78 Million | -32.91% |
| 2022-12-31 | $238.17 Million | +12.61% |
| 2021-12-31 | $211.50 Million | +40.85% |
| 2020-12-31 | $150.16 Million | -36.17% |
| 2019-12-31 | $235.23 Million | +69.72% |
| 2018-12-31 | $138.60 Million | +90.69% |
| 2017-12-31 | $72.68 Million | -26.15% |
| 2016-12-31 | $98.41 Million | -- |
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more